Historically, lung cancer is a disease that is diagnosed late, with limited treatment options that often have strong side effects and a poor response rate.
Yet in recent years, several exciting developments have begun to change this outlook.
In the latest instalment of ERS Vision, Professor Stephen Holgate and colleagues explore the recent advances in lung cancer diagnostics, changes in clinical trial design and improved standards of care, and discusses the optimistic future of lung cancer treatment.